2022
DOI: 10.3201/eid2809.220613
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022

Abstract: Our analysis of data collected from multiple epidemics in Hong Kong indicated a shorter serial interval and generation time of infections with the SARS-CoV-2 Omicron variant. The age-specific case-fatality risk for Omicron BA.2.2 case-patients without complete primary vaccination was comparable to that of persons infected with ancestral strains in earlier waves.

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
76
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 103 publications
(83 citation statements)
references
References 12 publications
6
76
1
Order By: Relevance
“…This case-control study extracted data using the population-level electronic health databases from Hong Kong Hospital Authority (HA) and the Department of Health (DH) of the Government of the Hong Kong Special Administrative Region, China in Hong Kong, China and enrolled DM patients aged ≥12 years, who had received zero to three doses of BNT162b2 or CoronaVac, during January to March 2022. This period was principally driven by the Omicron BA.2 variant ( 2 ), and these databases have previously been applied in several COVID-19 pharmacovigilance studies ( [3] , [4] , [5] , [6] ). Those who had a previous COVID-19 infection before the index date or had received the fourth dose of COVID-19 vaccine were excluded from the analysis.…”
mentioning
confidence: 99%
“…This case-control study extracted data using the population-level electronic health databases from Hong Kong Hospital Authority (HA) and the Department of Health (DH) of the Government of the Hong Kong Special Administrative Region, China in Hong Kong, China and enrolled DM patients aged ≥12 years, who had received zero to three doses of BNT162b2 or CoronaVac, during January to March 2022. This period was principally driven by the Omicron BA.2 variant ( 2 ), and these databases have previously been applied in several COVID-19 pharmacovigilance studies ( [3] , [4] , [5] , [6] ). Those who had a previous COVID-19 infection before the index date or had received the fourth dose of COVID-19 vaccine were excluded from the analysis.…”
mentioning
confidence: 99%
“…In testament, a retrospective cohort Hong Kong study of 5663 people infected during the Omicron BA.2.2. wave found the efficacy of Nm/R therapy to reduce hospitalization to be 53% in comparison to the 88% reduction demonstrated in the Nm/R trial [ 5 , 6 ]. Further, high profile individuals such as Anthony Fauci have elected for additional Nm/R therapy when experiencing rebound symptoms [ 6 ].…”
Section: Discussionmentioning
confidence: 97%
“…Our study had a number of limitations. A large wave of Omicron BA.2 occurred in Hong Kong in February-April 2022 with more than 1 million confirmed cases (14% of the population) and 9000 deaths (1.2 deaths per 1000 persons) [21]. Many infections likely were undocumented.…”
Section: Discussionmentioning
confidence: 99%